Home/Filings/4/0001140361-24-017566
4//SEC Filing

USMAN NASSIM 4

Accession 0001140361-24-017566

CIK 0001124105other

Filed

Apr 2, 8:00 PM ET

Accepted

Apr 3, 4:01 PM ET

Size

9.8 KB

Accession

0001140361-24-017566

Insider Transaction Report

Form 4
Period: 2024-04-01
USMAN NASSIM
DirectorPresident & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2024-04-01$6.93/sh+20,000$138,60021,636 total
  • Sale

    Common Stock

    2024-04-01$16.15/sh20,000$323,0001,636 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-04-0120,000301,652 total
    Exercise: $6.93Exp: 2033-10-31Common Stock (20,000 underlying)
Holdings
  • Common Stock

    (indirect: By IRA)
    77
  • Common Stock

    (indirect: By Trust)
    563
Footnotes (3)
  • [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023.
  • [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.80 to $17.15. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  • [F3]This option is vested in full.

Issuer

GYRE THERAPEUTICS, INC.

CIK 0001124105

Entity typeother

Related Parties

1
  • filerCIK 0001206872

Filing Metadata

Form type
4
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 4:01 PM ET
Size
9.8 KB